Last $7.66 USD
Change Today -0.30 / -3.77%
Volume 1.3M
ONVO On Other Exchanges
As of 8:04 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

organovo holdings inc (ONVO) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/18/13 - $13.65
52 Week Low
09/12/13 - $4.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORGANOVO HOLDINGS INC (ONVO)

organovo holdings inc (ONVO) Related Bloomberg News

View More Bloomberg News

organovo holdings inc (ONVO) Related Businessweek News

View More BusinessWeek News

organovo holdings inc (ONVO) Details

Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; and L’Oreal. The company was founded in 2007 and is headquartered in San Diego, California.

50 Employees
Last Reported Date: 08/8/14
Founded in 2007

organovo holdings inc (ONVO) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $362.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $289.1K
Chief Strategy Officer
Total Annual Compensation: $289.8K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $289.1K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2014.

organovo holdings inc (ONVO) Key Developments

Organovo Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014

Organovo Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company's total revenues were $0.1 million compared with $0.11 million a year ago. Loss from operations was $6.4 million compared with $3.7 million a year ago. Net loss was $6.4 million or $0.08 per basic and diluted share compared with $3.77 million or $0.06 per basic and diluted share a year ago. Net cash used by operating activities for the three months ended June 30, 2014 was approximately $3.4 million as compared to $2.7 million used in operating activities for the three months ended June 30, 2013. This $0.7 million increase in cash usage can be attributed to a $2.7 million increase in operating expenses, partially offset by an overall increase of $0.7 million of non-cash expenses included in operations, including share-based compensation, depreciation and amortization, and a decrease in working capital.

Organovo Announces Appointment of Gregory T. Lucier as Corporate Advisor

Organovo Holdings, Inc. announced that Gregory T. Lucier has been appointed as a corporate advisor. In the role, Mr. Lucier will advise Chief Executive Officer Keith Murphy and the executive management team on various corporate issues. Mr. Lucier was formerly Chairman and CEO of Life Technologies. Prior to his tenure at Life Technologies, Mr. Lucier was a corporate officer of General Electric Company.

Organovo Holdings, Inc., Annual General Meeting, Aug 20, 2014

Organovo Holdings, Inc., Annual General Meeting, Aug 20, 2014., at 09:00 Pacific Daylight. Location: 6275 Nancy Ridge Dr.. Agenda: To consider the election of Robert Baltera, Jr. and James Glover as Class III Directors Nominees; to ratify the appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm for the fiscal year ending March 31, 2015; to hold a non-binding advisory vote on the compensation of named executive officers; and to transact such other business as may properly be brought before the meeting or any adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONVO:US $7.66 USD -0.30

ONVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $7.84 USD -0.31
BioTime Inc $2.98 USD -0.01
Cytori Therapeutics Inc $1.38 USD +0.01
Fibrocell Science Inc $3.11 USD +0.01
NeoStem Inc $5.76 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation ONVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,674.2x
Price/Book 14.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,558.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORGANOVO HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at